Human Microbiome Market – Global Forecast to 2030
ヒトマイクロバイオーム市場は、予測期間中にCAGR31.5%で成長し、2024年の8億1,460万米ドルから2030年までに42億600万米ドルに達するとMarketsandMarketsでは予測しています。
「ヒトマイクロバイオーム市場 – 製品 (医薬品、プロバイオティクス、プレバイオティクス、シンバイオティクス)、疾患 (感染症、胃腸、内分泌および代謝)、種類 (BCT/FMT、生菌製剤)、エンドユーザー (病院、診療所、長期治療) – 2030年までの世界予測 – Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) – Global Forecast to 2030」は世界のヒトマイクロバイオーム市場を調査し、主要セグメント別に分析・予測したMarketsandMarkets（マーケッツアンドマーケッツ）の市場調査報告書です。
マイクロバイオーム市場の注目ポイント
- 2023年のヒトマイクロバイオームの製品別市場においては、プロバイオティクスは最大シェアを占めた。
- 2023年のヒトマイクロバイオームの疾患別市場においては、胃腸疾患が最大シェアを占めた。
- 2023年のヒトマイクロバイオームのタイプ別市場においては、生菌製剤（LBPs）が最大シェアを占めた。
- 2023年のヒトマイクロバイオームのエンドユーザ市場においては、病院およびクリニックが最大シェアを占めた。
- 2023年のヒトマイクロバイオームの地域別市場においては、北米が最大シェアを占めた。
The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period.
Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the Human Microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
List of Companies Profiled in the Report:
- Nestle S.A. (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- BiomeBank (Australia)
- Seed Health, Inc. (US)
- International Flavors & Fragrances Inc (US)
- Pendulum (US)
- BioHM Health Inc. (US)
- Actial Farmaceutica SRL (Italy)
- Optibiotix Health plc (UK)
- Resbiotic (US)
- Infinant Health Inc (US)
- Biogaia AB (Sweden)
- Exegi Pharma Llc (US)
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Start-Ups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the Human Microbiome market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market
- Competitive Assessment: Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US) among others in the market.